Raimundo de Andrés

2.1k total citations
19 papers, 415 citations indexed

About

Raimundo de Andrés is a scholar working on Surgery, Cardiology and Cardiovascular Medicine and Physiology. According to data from OpenAlex, Raimundo de Andrés has authored 19 papers receiving a total of 415 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Surgery, 4 papers in Cardiology and Cardiovascular Medicine and 4 papers in Physiology. Recurrent topics in Raimundo de Andrés's work include Lipoproteins and Cardiovascular Health (13 papers), Nitric Oxide and Endothelin Effects (4 papers) and Coronary Interventions and Diagnostics (3 papers). Raimundo de Andrés is often cited by papers focused on Lipoproteins and Cardiovascular Health (13 papers), Nitric Oxide and Endothelin Effects (4 papers) and Coronary Interventions and Diagnostics (3 papers). Raimundo de Andrés collaborates with scholars based in Spain, Chile and Australia. Raimundo de Andrés's co-authors include Rodrigo Alonso, Antonio López‐Farré, Luís Rico, Lina Badimón, Pedro Mata, Antonio García‐Méndez, Francisco Fuentes, José Luis Díaz-Díaz, Jerónimo Farré and Leopoldo Pérez de Isla and has published in prestigious journals such as Journal of the American College of Cardiology, European Heart Journal and Atherosclerosis.

In The Last Decade

Raimundo de Andrés

18 papers receiving 408 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Raimundo de Andrés Spain 11 219 142 76 76 54 19 415
Curtis Rambaran United Kingdom 9 271 1.2× 182 1.3× 101 1.3× 67 0.9× 58 1.1× 19 462
Federico Bigazzi Italy 12 256 1.2× 150 1.1× 90 1.2× 63 0.8× 105 1.9× 47 462
Koji Yanagi Japan 10 316 1.4× 107 0.8× 177 2.3× 99 1.3× 51 0.9× 19 422
Razvan T. Dadu United States 8 179 0.8× 118 0.8× 32 0.4× 37 0.5× 70 1.3× 16 403
Y Nishizawa Japan 13 153 0.7× 113 0.8× 147 1.9× 70 0.9× 117 2.2× 32 596
Charles Solymoss Canada 5 294 1.3× 213 1.5× 60 0.8× 44 0.6× 51 0.9× 6 443
Adam Taleb United States 7 274 1.3× 129 0.9× 62 0.8× 105 1.4× 151 2.8× 12 536
Shenghua Yang China 14 138 0.6× 84 0.6× 98 1.3× 123 1.6× 190 3.5× 25 536
Marek Szołkiewicz Poland 14 160 0.7× 54 0.4× 44 0.6× 42 0.6× 127 2.4× 44 511
Oreste Arcucci Italy 8 122 0.6× 232 1.6× 71 0.9× 40 0.5× 132 2.4× 10 458

Countries citing papers authored by Raimundo de Andrés

Since Specialization
Citations

This map shows the geographic impact of Raimundo de Andrés's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Raimundo de Andrés with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Raimundo de Andrés more than expected).

Fields of papers citing papers by Raimundo de Andrés

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Raimundo de Andrés. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Raimundo de Andrés. The network helps show where Raimundo de Andrés may publish in the future.

Co-authorship network of co-authors of Raimundo de Andrés

This figure shows the co-authorship network connecting the top 25 collaborators of Raimundo de Andrés. A scholar is included among the top collaborators of Raimundo de Andrés based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Raimundo de Andrés. Raimundo de Andrés is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Alonso, Rodrigo, José Luis Díaz-Díaz, Francisco Fuentes, et al.. (2024). Improved lipid-lowering treatment and reduction in cardiovascular disease burden in homozygous familial hypercholesterolemia: The SAFEHEART follow-up study. Atherosclerosis. 393. 117516–117516. 7 indexed citations
2.
Isla, Leopoldo Pérez de, José Luis Díaz-Díaz, Manuel Jesús Romero-Jiménez, et al.. (2024). Characteristics of Coronary Atherosclerosis Related to Plaque Burden Regression During Treatment With Alirocumab: The ARCHITECT Study. Circulation Cardiovascular Imaging. 17(1). 8 indexed citations
3.
Alonso, Rodrigo, Ovidio Muñiz-Grijalvo, José Luis Díaz-Díaz, et al.. (2021). Efficacy of PCSK9 inhibitors in the treatment of heterozygous familial hypercholesterolemia: A clinical practice experience. Journal of clinical lipidology. 15(4). 584–592. 11 indexed citations
4.
Isla, Leopoldo Pérez de, Rodrigo Alonso, José Juan Gómez de Diego, et al.. (2020). Coronary plaque burden, plaque characterization and their prognostic implications in familial hypercholesterolemia: A computed tomographic angiography study. Atherosclerosis. 317. 52–58. 19 indexed citations
5.
Masana, L., José López‐Miranda, Fernando Civeira, et al.. (2020). Perfil clínico de los pacientes tratados con evolocumab en unidades de lípidos/medicina interna en España. Estudio observacional (RETOSS-IMU). Clínica e Investigación en Arteriosclerosis. 32(5). 183–192. 3 indexed citations
6.
Isla, Leopoldo Pérez de, Gerald F. Watts, Rodrigo Alonso, et al.. (2020). Lipoprotein(a), LDL-cholesterol, and hypertension: predictors of the need for aortic valve replacement in familial hypercholesterolaemia. European Heart Journal. 42(22). 2201–2211. 28 indexed citations
7.
Masana, L., José López‐Miranda, Fernando Civeira, et al.. (2020). Clinical profile of patients treated with evolocumab in lipid/internal medicine units of Spain. Observational study (RETOSS-IMU). Clínica e Investigación en Arteriosclerosis (English Edition). 32(5). 183–192.
8.
Saltijeral, Adriana, Leopoldo Pérez de Isla, Rodrigo Alonso, et al.. (2017). Consecución de objetivos terapéuticos de colesterol LDL en niños y adolescentes con hipercolesterolemia familiar. Registro longitudinal SAFEHEART. Revista Española de Cardiología. 70(6). 444–450. 29 indexed citations
9.
Alonso, Rodrigo, José Luis Díaz-Díaz, Francisco Arrieta, et al.. (2016). Clinical and molecular characteristics of homozygous familial hypercholesterolemia patients: Insights from SAFEHEART registry. Journal of clinical lipidology. 10(4). 953–961. 34 indexed citations
10.
Saltijeral, Adriana, Leopoldo Pérez de Isla, Rodrigo Alonso, et al.. (2016). Attainment of LDL Cholesterol Treatment Goals in Children and Adolescents With Familial Hypercholesterolemia. The SAFEHEART Follow-up Registry. Revista Española de Cardiología (English Edition). 70(6). 444–450. 28 indexed citations
11.
Alonso, Rodrigo, et al.. (2015). Homozygous familial hypercholesterolemia. First case in Spain treated with lomitapide, an inhibitor of the synthesis of lipoproteins with apolipoprotein B. Medicina Clínica (English Edition). 145(5). 229–230. 6 indexed citations
12.
Mateos‐Cáceres, Petra J., Antonio García‐Méndez, Antonio López‐Farré, et al.. (2004). Proteomic analysis of plasma from patients during an acute coronary syndrome. Journal of the American College of Cardiology. 44(8). 1578–1583. 99 indexed citations
13.
García‐Méndez, Antonio, Jerónimo Farré, Lourdes Sánchez de Miguel, et al.. (2002). Prior aspirin use in unstable angina patients with modified plasma inflammatory markers and endothelial nitric oxide synthase in neutrophils. European Journal of Clinical Investigation. 32(12). 895–900. 10 indexed citations
14.
Jiménez, Ana, Inmaculada Millás, Jerónimo Farré, et al.. (2002). Efecto de la inhibición de la HMG-CoA reductasa sobre la proteína inductora de disfunción endotelial en conejos hipercolesterolémicos. Revista Española de Cardiología. 55(11). 1151–1158. 6 indexed citations
15.
Miguel, Lourdes Sánchez de, Mercedes Montón, Antonio López‐Farré, et al.. (2002). Nitric oxide production by neutrophils obtained from patients during acute coronary syndromes: expression of the nitric oxide synthase isoforms. Journal of the American College of Cardiology. 39(5). 818–825. 26 indexed citations
16.
López‐Farré, Antonio, Juan A. Rodríguez-Feo, Juan Gómez Rivas, et al.. (2002). Reduction of the soluble cyclic GMP vasorelaxing system in the vascular wall of stroke-prone spontaneously hypertensive rats: effect of the α1-receptor blocker doxazosin. Journal of Hypertension. 20(3). 463–470. 36 indexed citations
17.
18.
Rodríguez-Feo, Juan A., Antonio Núñez, Luís Rico, et al.. (2001). Doxazosina y guanilato ciclasa soluble en un modelo de ratas hipertensas. Revista Española de Cardiología. 54(7). 880–886. 3 indexed citations
19.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Curtis Rambaran Breakdown of academic impact, for papers by Federico Bigazzi Breakdown of academic impact, for papers by Koji Yanagi Breakdown of academic impact, for papers by Razvan T. Dadu Breakdown of academic impact, for papers by Y Nishizawa Breakdown of academic impact, for papers by Charles Solymoss Breakdown of academic impact, for papers by Adam Taleb Breakdown of academic impact, for papers by Shenghua Yang Breakdown of academic impact, for papers by Marek Szołkiewicz Breakdown of academic impact, for papers by Oreste Arcucci
Rankless by CCL
2026